International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic dataDaniel A. Arber, Michael R. Savona, Mignon L. Loh et al.|Blood|2022Cited by 2.7k
Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 studyHagop M. Kantarjian, Susan O’Brien, Deborah A. Thomas et al.|The Lancet Oncology|2012Cited by 411
Ph-like acute lymphoblastic leukemia: a high-risk subtype in adultsNitin Jain, Marina Konopleva, Kathryn G. Roberts et al.|Blood|2016Cited by 385
Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomicsKiyomi Morita, Koichi Takahashi, Feng Wang et al.|Nature Communications|2020Cited by 383
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trialCourtney D. DiNardo, Marina Konopleva, Abhishek Maiti et al.|The Lancet Haematology|2020Cited by 330